UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of
1934
Date of
Report (Date of earliest event reported): June 24,
2021
|
AMERICAN BIO
MEDICAL CORPORATION
|
||
|
(Exact
name of registrant as specified in its charter)
|
||
|
New
York
|
0-28666
|
14-1702188
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification Number)
|
|
|
|
|
|
122 Smith Road, Kinderhook,
NY
|
12106
|
|
(Address of
principal executive offices)
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: 518-758-8158
Not applicable
(Former name or former address, if changed since last
report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see
General Instruction A.2.
below):
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
Securities
registered pursuant to Section 12(b) of the Act:
|
Title of each
class
|
Trading
Symbol(s)
|
Name of each exchange on which
registered
|
|
Common
|
ABMC
|
OTC
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this
chapter).
Emerging
growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 5.07
Submission of Matters to a Vote of Security Holders
At the
Annual Meeting of the Shareholders of the Company held on June 24,
2021 (the “Annual Meeting”), at the Company’s
corporate offices in Kinderhook, New York, the following matters
were voted upon.
|
Total Shares in Attendance:
|
25,562,751
|
Total Shares Outstanding (as of April 27, 2021)
40,203,476
|
|
Percent of Shares Voted:
|
63.6%
|
PROPOSAL
NUMBER 1 – ELECTION OF DIRECTORS
|
Director
|
For
|
Percent
|
Withheld
|
Percent
|
Broker
Non-Votes
|
|
|
|
|
|
|
|
|
Peter
Jerome
|
4,123,947
|
35%
|
7,658,978
|
65%
|
13,679,826
|
|
Melissa
Waterhouse
|
3,363,301
|
28.5%
|
8,419,624
|
71.5%
|
13,679,826
|
In
addition to the shares indicated above, there were 100,000 shares
uncast for Proposal Number 1.
PROPOSAL
NUMBER 2 – RATIFICATION OF AUDITORS
|
|
Percent
|
Against
|
Percent
|
Abstain
|
Percent
|
Broker
Non-Votes
|
|
20,867,317
|
81.6%
|
4,692,397
|
18.4%
|
3,037
|
0.01%
|
0
|
PROPOSAL
NUMBER 3 – APPROVAL OF AN AMENDMENT TO THE COMPANY’S
CERTIFICATE OF INCORPORATION TO INCREASE THE NUMBER OF AUTHORIZED
COMMON SHARES FROM 50,000,000 TO 75,000,000 COMMON
SHARES
|
For
|
Percent
|
Against
|
Percent
|
Abstain
|
Percent
|
Broker
Non-Votes
|
|
16,503,038
|
64.6%
|
8,976,835
|
35.1%
|
82,878
|
0.3%
|
0
|
A
description of the proposals can be found in the Company’s
definitive proxy statement for the Annual Meeting filed with the
U.S. Securities and Exchange Commission on May 4,
2021.
The
nominees for election to the Board of Directors were each elected
for a three-year term ending in 2024, or until their successor is
elected and duly qualified. In addition to the directors elected at
the Annual Meeting, Jean Neff continued her term of office after
the Annual Meeting.
There
were no other matters voted upon or discussed at the Annual Meeting
other than the Proposals noted above.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
AMERICAN BIO MEDICA
CORPORATION (Registrant)
|
|
|
|
|
|
|
|
|
Date:
June
29, 2021
|
By:
|
/s/ Melissa A.
Waterhouse
|
|
|
|
|
Melissa A. Waterhouse |
|
|
|
|
Chief Executive
Officer (Principal Executive Officer)
Principal
Financial Officer
|
|